Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma
NCT06594991Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of fianlimab, cemiplimab, ipilimumab in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2024; status: recruiting.
02
Drugs
fianlimabcemiplimabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06594991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594991.